ClinicalTrials.gg
CompletedNCT06541730DA168Updated Apr 16, 2025

A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects

A Phase 1 interventional study of DA-302168S and Placebo of DA-302168S in Overweight and Obesity, sponsored by Chendu DIAO Pharmaceutical Group CO., LTD.. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-04-16.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Chendu DIAO Pharmaceutical Group CO., LTD. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
397th of 502
48 · median 120
Started
2024
with 76 others
Phase 1
93 of 600
29 open now
Registered
291st of 600
by date

Among the 600 studies in Obesity with a site in China, this one is the 397th largest by enrollment of the 502 interventional ones that give a count, is one of 77 that started in 2024, is one of 93 in phase 1, and was the 291st registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 600 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 48 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Chendu DIAO Pharmaceutical Group CO., LTD. is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18\~60 years old, male and female.
  • Weight: male ≥50 kg, female ≥45 kg, (BMI) in the range of 24.0 to 35.0 kg/m2.
  • Stable weight in the 3 months prior to screening (self-reported weight change less than 5%).
  • Subject and his or her spouse or partner did not plan to become pregnant or plan to donate sperm or ovums from 14 days prior to screening to 3 months after the last dose, and agreed to use at least one acceptable method of effective .
  • Written prior to any study specific procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects with secondary obesity, such as obesity caused by metabolic diseases (such as Cushing's syndrome, decreased thyroid function, etc.) or drug-induced obesity (such as , tricyclic antidepressants, atypical antipsychotics, etc.)
  • Subjects with cardiovascular and cerebrovascular diseases, including a history of angina pectoris, myocardial infarction, stroke or severe peripheral arterial circulation disorder, or within 1 year before signing the ICF; There are risk factors for tip torsion ventricular tachycardia. The presence of untreated severe arrhythmias, such as sick sinus syndrome, second or third degree atrioventricular block; Heart Function Class II-IV heart failure.
  • Previous history or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or multiple endocrine adenomatosis type 2;
  • Subjects with acute pancreatitis or acute cholecystitis within 3 months before signing the ICF, or with chronic pancreatitis in the past, a history of symptomatic gallbladder (such as multiple gallstones, etc.), or a history of pancreatic injury and other high-risk factors that may lead to pancreatitis;
  • Had any within 5 years prior to signing the ICF (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix);
  • The presence of concomitant diseases, including but not limited to diseases of the respiratory system, digestive system, nervous system, genitourinary system, blood system, endocrine system, etc. that are determined by the investigator to affect the safety of the subject or the findings of the study;
  • Those who had previously undergone weight loss surgery (excluding acupuncture for weight loss, liposuction and abdominal fat removal 1 year before screening) or planned to undergo surgery for obesity during the study period, such as gastric bypass or gastric banding;
  • Subjects who have experienced severe hypoglycemia or recurrent symptomatic hypoglycemia (≥2 times within half a year) in the past;
  • Subjects who have a history of specific allergies (asthma, urticaria, eczema, etc.) or allergies, or are allergic to any component of the investigatory drug or preparation, or are allergic to other GLP-1RA drugs or drugs that have a mechanism of activating GLP-1 receptor;
  • ≥6.5%, or fasting blood glucose ≥7.0 mmol/L or ≤3.9 mmol/L at screening period, or previously diagnosed with type 1 diabetes, type 2 diabetes, or other specific type of diabetes;
  • Subjects with a history of thyroid dysfunction who still need drug therapy at screening, or abnormal thyroid function results at screening that are clinically significant;
  • A history of moderate to severe depression, anxiety disorder, or a history of serious mental illness, such as schizophrenia or bipolar disorder; Or previous suicidal tendencies or behaviors;
  • A history of dysphagia or any gastrointestinal disorder that affects drug absorption (as determined by the investigator);
  • Subjects who cannot tolerate venipunction, have a history of needle fainting and blood fainting;
  • Lactose intolerant;
  • Those who test positive for drug abuse or have a history of drug abuse in the past five years or have used drugs in the three months prior to screening;
  • Subjects who had received a glucose-lowering drug such as GLP-1 receptor agonist, dipeptidyl peptidase-4 (DPP-4) inhibitor, sodium-glucose cotransporter-2 (SGLT-2) inhibitor, insulin, metformin, insulin secretagotropin, or thiazolidinedione (TZD) within 3 months prior to screening;
  • Use of drugs that have an impact on body weight in the 3 months prior to screening, including any approved or unapproved weight loss drugs, such as orlistat, lorcasserin, phentermine/topiramate, naltrexone/bupropion, etc.) or Chinese herbs, health products, meal replacements, etc., that affect body weight; Systemic steroid hormone use (intravenous, oral or intra-articular administration), tricyclic antidepressants, psychiatric medications or sedatives (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenethazine, chlorpromazine, thiridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts); Note: Except cumulative or continuous use of systemic sex hormones for less than 14 days;
  • Those who have participated in other drug clinical trials and received any drug in clinical trials within 3 months prior to screening;
  • Subjects who have donated blood or lost blood ≥400 mL, received blood transfusion or used blood products in the 3 months prior to screening;
  • Smokers or smokers who smoked an average of ≥5 cigarettes per day in the 3 months prior to screening, or who could not stop using any tobacco products during the study;
  • Alcoholics or regular drinkers in the three months prior to screening, i.e. those who consume more than 14 standard units of alcohol per week (1 unit of alcohol =360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) or who test positive for blood alcohol at baseline, or who cannot stop using any alcohol-containing products during the test period;
  • Untreated or poorly controlled hypertension (defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg) at the screening period
  • Mean interval (corrected by Fridericia's formula) of the three supine 12-lead measurements was >450 msec;
  • Periodclinical laboratory examination (local laboratory) results showed any of the following abnormal subjects (re-confirmed once within 1 week if necessary) : (ALT) ≥2.0× (ULN); Aspartate aminotransferase (AST) ≥2.0×ULN; Blood total (TBIL) ≥1.5×ULN; Amylase or lipase >1.5×ULN; Calcitonin ≥50 ng/L; Estimated (eGFR) \< 60 mL/min/1.73 m2 [CKD-EPI formula, see Appendix 4]; Triglyceride (TG) > 500 mg/dl (5.65 mmol/L);
  • Subjects tested positive for surface antigen (HBsAg), virus antibody (HCVAb), antibody (HIVAb), or Treponema pallidum antibody (TP-Ab);
  • Female subjects who are pregnant or breastfeeding, or who test positive for pregnancy;
  • Those who consumed an average of excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup =250 mL) per day during the 3 months prior to screening, or had consumed tea, coffee and/or caffeinated beverages within 48 hours prior to initial dosing, or could not stop drinking during the study;
  • Subjects who have been chronically consuming drinks or foods rich in xanthine or grapefruit, or who have taken any products rich in xanthine or grapefruit within 48 hours before the first dose;
  • Any other factors that might affect the evaluation of the relevant indicators for this study identified by the investigator that were not suitable for participation.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    DA-302168S

    Drug: DA-302168S

  • Placebo comparator
    Placebo of DA-302168S

    Drug: Placebo of DA-302168S

Interventions

  • Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

  • DrugPlacebo of DA-302168S

    Titration was used in this study, and the initial plan was to dose titration in cohort 1 (15 mg dose group). The titration regimen and titration dose for subsequent cohorts will be determined based on the results of cohort 1, including the starting dose of titration, frequency of administration, and titration amplitude.

07

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0.

    Time frame: Through study completion, an average of 49 days.

Secondary outcomes

  1. Cmax

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  2. Tmax

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  3. AUC0-t

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  4. Cmin

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  5. PTR

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  6. Swing

    Plasma samples were collected at different points for pharmacokinetic analysis.

    Time frame: Day 7 to day 8, day 14 to day 15, day 21 to day 22, day 28.

  7. Body Weight

    Percentage change in body weight from baseline.

    Time frame: Day 1, 8, 15, 22, 29.

  8. Changes in glycosylated hemoglobin (HbA1c) relative to baseline after 28 days of administration.

    Blood samples will be assessed for HbA1c (glycated hemoglobin)

    Time frame: Day 1, 29.

08

Study locations

1 site
  • The Second Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230000, China
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in Jan 2025, 5 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 7, 2024
StartActual
Aug 30, 2024
Primary completionActual
Jan 30, 2025
CompletionActual
Jan 30, 2025
Last update
Apr 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06541730
Responsible party
Sponsor
First posted
Aug 7, 2024
Start date
Aug 30, 2024
Primary completion
Jan 30, 2025
Completion
Jan 30, 2025
Last update
Apr 16, 2025

Study contacts

Wei Hu, Doctor
principal investigator · The Second Hospital of Anhui Medical University
Yi Jun Du, Doctor
principal investigator · The Second Hospital of Anhui Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: DA-302168S

Start the discussion